Int this website J Cancer 2003; 103: 142–144. 18 Mocroft A, Kirk O, Clumeck N et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003: the EuroSIDA Study. Cancer 2004; 100: 2644–2654. 19 Engels EA, Pfeiffer RM, Goedert JJ et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS

2006; 20: 1645–1654. 20 Franceschi S, Maso LD, Rickenbach M et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer 2008; 99: 800–804. 21 Guiguet M, Boué F, Cadranel J et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10: 1152–1159. 22 Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987–1999. J Acquir Immune Defic Syndr 2002; 29: 378–387. 23 Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011; 117: 1089–1096. 24 Lodi S, Guiguet M, Costagliola D et al. Kaposi sarcoma incidence Caspase activity assay and survival among HIV-infected homosexual men

after HIV seroconversion. J Natl Cancer Inst 2010; 102: 784–792. 25 Pipkin S, Scheer S, Okeigwe I et al. The effect of HAART and calendar period on Kaposi’s sarcoma and non-Hodgkin lymphoma: results of a match between an AIDS and cancer registry. AIDS 2011; 25: 463–471. 26 Shiels MS, Pfeiffer RM, Gail MH et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011; 103: 753–762. 27 Sitas F, Carrara H, Beral V et al. Antibodies

against human herpesvirus 8 in black South African patients with cancer. N Engl J Med 1999; 340: 1863–1871. 28 Bassett MT, Chokunonga E, Mauchaza B et al. Cancer in the African population of Harare, Zimbabwe, 1990–1992. Int J Cancer 1995; 63: 29–36. 29 Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer 2000; 82: 1585–1592. 30 Parkin DM, Sitas F, Chirenje M et al. Part I: Cancer DOCK10 in indigenous Africans–burden, distribution, and trends. Lancet Oncol 2008; 9: 683–692. 31 Mosam A, Carrara H, Shaik F et al. Increasing incidence of Kaposi’s sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983–2006). Int J STD AIDS 2009; 20: 553–556. 32 Chokunonga E, Borok MZ, Chirenje ZM et al. Trends in the incidence of cancer in the black population of Harare, Zimbabwe 1991–2010. Int J Cancer 2013; 133: 721–729. 33 Mosam A, Uldrick TS, Shaik F et al. An evaluation of the early effects of a combination antiretroviral therapy programme on the management of AIDS-associated Kaposi’s sarcoma in KwaZulu-Natal, South Africa. Int J STD AIDS 2011; 22: 671–673. 34 Casper C.